In-Depth Examination of Segments, Industry Developments, and Key Players in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is positioned for remarkable expansion in the coming years. Driven by several advancements in medical science and patient care, this sector is set to witness substantial growth through 2030. Let's explore the market size projections, key players, trends influencing the industry, and the main segments shaping this evolving field.

Projected Growth Trajectory of the ATTR-CM Treatment Market
The market for transthyretin amyloid cardiomyopathy treatments is anticipated to experience significant growth, reaching a value of $45.09 billion by 2030. This corresponds to a robust compound annual growth rate (CAGR) of 27.6% during the forecast period. Such expansion is primarily fueled by the rising adoption of precision medicine techniques, rapid progress in next-generation gene-silencing therapies, increasing investments in rare disease drug development pipelines, improved patient access to cutting-edge cardiac diagnostic tools, and a growing emphasis on treatments that modify the course of the disease. Key trends expected to influence the market include greater use of transthyretin stabilizer therapies, adoption of RNAi-based treatments, enhanced focus on early diagnosis and ongoing disease monitoring, expansion of personalized treatment plans, and boosted funding aimed at rare cardiac disease research.

Download a free report of the transthyretin amyloid cardiomyopathy (attr-cm) treatment market report:
https://www.thebusinessresearchcompany.com/report/transthyretin-amyloid-cardiomyopathy-attr-cm-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Core Factors Accelerating Growth in the ATTR-CM Treatment Market
A significant driver behind the market's growth is the advancement and implementation of precision medicine, allowing therapies to be tailored to individual patient profiles. This personalized approach enhances treatment effectiveness and patient outcomes, especially in complex conditions like ATTR-CM.
Moreover, increasing investments from pharmaceutical and biotech companies into rare disease drug pipelines are catalyzing innovation and speeding up the introduction of novel therapies. Enhanced patient access to sophisticated cardiac diagnostics also plays a crucial role in early detection and timely intervention, improving overall disease management and treatment success.

Leading Companies in the ATTR-CM Treatment Market
Key industry players dominating the transthyretin amyloid cardiomyopathy treatment arena include Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Intellia Therapeutics Inc, SOM Biotech S L, Ionis Pharmaceuticals Inc, Eidos Therapeutics Inc, Prothena Corporation plc, Neurimmune Holding AG, Corino Therapeutics Inc, CRISPR Therapeutics AG, YolTech Therapeutics Co Ltd, Silence Therapeutics plc, and Akcea Therapeutics Inc.
A notable development occurred in March 2024 when Bayer AG, a German pharmaceutical giant, secured exclusive European marketing rights for acoramidis from BridgeBio Pharma in a deal valued at up to $310 million. This acquisition enables Bayer to leverage its established cardiovascular infrastructure to introduce a new oral treatment for ATTR-CM across Europe, thereby strengthening its position within the rare cardiovascular disease treatment market. BridgeBio Pharma, based in the US, is focused on genetic and rare diseases, developing acoramidis as a potent, orally administered small-molecule transthyretin stabilizer designed specifically for ATTR-CM therapy.

View the full transthyretin amyloid cardiomyopathy (attr-cm) treatment market report:
https://www.thebusinessresearchcompany.com/report/transthyretin-amyloid-cardiomyopathy-attr-cm-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Reshaping the ATTR-CM Treatment Landscape
Companies in this field are increasingly concentrating on innovative oral medications that target transthyretin proteins to stabilize them or prevent amyloid fibril accumulation in the heart. Oral prescription therapies, typically administered as tablets, capsules, or liquids, are becoming central to managing ATTR-CM effectively.
For instance, in November 2024, BridgeBio Pharma Inc. achieved FDA approval for Attruby (acoramidis) as a treatment for adults with ATTR-CM. This therapy works by stabilizing the TTR protein, which has been shown to reduce heart-related fatalities and hospital admissions. Clinical trials indicate that Attruby is well-tolerated by patients and delivers rapid benefits by addressing the underlying cause of the disease.

Market Segmentation Highlighting the ATTR-CM Treatment Industry
This market is categorized based on type, indication, and end-user segments:
1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), RNAi Therapy, and Other Types
2) By Indication: Wild type ATTR Amyloidosis and Hereditary ATTR Amyloidosis
3) By End-Users: Hospitals, Homecare, Specialty Clinics, and Other End Users

Further sub-segments include:
- Transthyretin Stabilizers such as Tafamidis and Diflunisal
- NSAIDs including Aspirin and Ibuprofen
- RNAi Therapies like Patisiran and Vutrisiran
- Other Types comprising Gene Silencing Therapies, Immunotherapy Approaches, and Emerging Small Molecule Treatments

Each segment reflects the diverse treatment approaches and growing sophistication within the ATTR-CM therapeutic landscape, catering to varying patient needs and advancing clinical care.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.